Secaucus-based Quest Diagnostics completed its previously announced acquisition of PathAI Diagnostics from Boston-based PathAI, with the goal to accelerate the adoption of artificial intelligence and digital pathology to improve the diagnosis of cancer and other diseases.
PathAI will continue to support its biopharmaceutical clients with end-to-end clinical trial services capabilities at its biopharma lab, which is separate and distinct from the diagnostic laboratory business. The transaction will support PathAI’s strategy to scale its investments in AI technology and expand its software and algorithm business.
In connection with the acquisition, the PathAI Diagnostics state-of-the-art digitized laboratory in Memphis has been rebranded as AmeriPath and will act as the national AI and digital research & development and solutions center supporting Quest’s specialty pathology businesses, AmeriPath and Dermpath Diagnostics.
In addition, PathAI and Quest have formed separate agreements to further accelerate the adoption of AI and digital pathology based on their strengths and scale. Specifically, Quest will license PathAI’s AISight digital pathology image management system to support Quest’s pathology laboratories and customer sites in the U.S. Quest is also a preferred partner of lab services for PathAI’s biopharmaceutical clients. In addition, PathAI and Quest may also collaborate on developing AI algorithms with potential research and clinical applications.
